OncoMatch/Clinical Trials/NCT05986318
Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease
Is NCT05986318 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Dexamethasone Oral for lung cancer.
Treatment: Dexamethasone Oral — In this double-blind phase II randomized controlled trial, patients with lung cancer or ≤2 oligometastatic pulmonary lesions and a concomitant diagnosis of ILD who are planned for radical Radiation Therapy (RT) will be randomized using a 2 x 2 factorial design to oral N-acetylcysteine (NAC) versus placebo, and also to short course corticosteroids versus placebo.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Cannot have received: lung radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05986318 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior lung radiotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify